Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 22,363 Shares

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 447,278 shares at an average price of $1.54, totaling approximately $688,808.
• The company's shares are scheduled for a 1-20 reverse split on September 19th, 2023, affecting the number of shares owned by shareholders.
• Vor Biopharma's current stock performance shows a market cap of $192.56 million, with a one-year trading range from $0.13 to $3.29.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 22,363 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40. Following the completion of the transaction, the insider owned 1,639,060 shares in the company, valued at $50,483,048. This represents a 1.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The shares were sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The shares were sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The shares were sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The shares were sold at an average price of $40.00, for a total value of $898,440.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The shares were sold at an average price of $39.40, for a total value of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 22,650 shares of Vor Biopharma stock. The shares were sold at an average price of $38.60, for a total value of $874,290.00.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 27,730 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total value of $1,109,200.00.

Vor Biopharma Stock Performance

Shares of VOR traded up $0.64 during trading hours on Monday, hitting $27.88. The company had a trading volume of 180,737 shares, compared to its average volume of 379,342. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80. The firm has a fifty day moving average price of $40.37 and a 200-day moving average price of $22.93. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of -16.90 and a beta of 2.05.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently bought and sold shares of VOR. OMERS ADMINISTRATION Corp purchased a new position in Vor Biopharma during the first quarter valued at approximately $100,000. Northern Trust Corp raised its position in Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after acquiring an additional 44,252 shares in the last quarter. Money Concepts Capital Corp raised its position in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. Two Sigma Investments LP raised its position in Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Vor Biopharma in the first quarter valued at approximately $140,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on VOR. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $121.33.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.